Industry News

Novaliq announces phase 1 study for dry eye solution

Novaliq GmbH announced the commencement of a phase 1 study for CyclASol (cyclosporine solution) following U.S. and European patent approval of the solution for treating dry eye syndrome.

CyclASol is a 0.05% clear cyclosporine solution that is available in multidose and preservative-free bottles, according to a company press release. The company reported that the solution was developed from Novaliq’s semifluorinated alkane drug delivery platform, EyeSol, which enhances the therapeutic effect of poorly soluble drugs.

According to the release, in 2013 Novaliq finalized its fifth round of financing for $18.1 million to increase the prescription and over-the-counter product development programs based on its semifluorinated alkane technology.

Novaliq GmbH announced the commencement of a phase 1 study for CyclASol (cyclosporine solution) following U.S. and European patent approval of the solution for treating dry eye syndrome.

CyclASol is a 0.05% clear cyclosporine solution that is available in multidose and preservative-free bottles, according to a company press release. The company reported that the solution was developed from Novaliq’s semifluorinated alkane drug delivery platform, EyeSol, which enhances the therapeutic effect of poorly soluble drugs.

According to the release, in 2013 Novaliq finalized its fifth round of financing for $18.1 million to increase the prescription and over-the-counter product development programs based on its semifluorinated alkane technology.